Compare FINW & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINW | ADAG |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.7M | 254.4M |
| IPO Year | 2021 | 2020 |
| Metric | FINW | ADAG |
|---|---|---|
| Price | $14.50 | $3.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 20.8K | ★ 132.2K |
| Earning Date | 04-30-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.51 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $160.48 | N/A |
| Revenue Next Year | $35.27 | N/A |
| P/E Ratio | $72.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.82 | $1.44 |
| 52 Week High | $22.49 | $4.75 |
| Indicator | FINW | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 58.69 |
| Support Level | $12.82 | $3.16 |
| Resistance Level | $17.39 | $3.99 |
| Average True Range (ATR) | 0.49 | 0.35 |
| MACD | 0.20 | 0.05 |
| Stochastic Oscillator | 93.01 | 70.94 |
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.